Nan Fang Du Shi Bao·2025-10-27 08:49Core Viewpoint - WuXi AppTec has reported a strong performance in Q3 2025, with revenue and net profit both increasing, while also announcing a strategic focus on its CRDMO (Contract Research, Development, and Manufacturing) core business by divesting its clinical operations [1][2][5]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 32.86 billion yuan, a year-on-year increase of 18.6%, and a non-GAAP net profit attributable to shareholders of 9.52 billion yuan, up 42.5% [2][3]. - In Q3 alone, revenue reached 12.06 billion yuan, reflecting a 15.3% year-on-year growth, while non-GAAP net profit surged by 73.8% to 3.94 billion yuan [2][3]. Business Segments - The chemical business was the largest contributor to revenue, generating 25.98 billion yuan, a 29.3% increase year-on-year, driven by strong performance in small molecule drug discovery and development [4][5]. - The company reported a backlog of orders in its continuing operations amounting to 59.88 billion yuan, a 41.2% increase year-on-year, indicating robust demand [4]. Strategic Moves - WuXi AppTec announced the sale of its clinical research subsidiaries, Shanghai Kande Hongyi Medical Research Co., Ltd. and Shanghai WuXi Jishi Pharmaceutical Technology Co., Ltd., to Hillhouse Capital for a base price of 2.8 billion yuan [7][10]. - The divestiture is part of the company's strategy to concentrate on its CRDMO business model, which is expected to enhance its global capabilities and operational efficiency [12]. Operational Efficiency - The company has focused on optimizing production processes and improving operational efficiency, which has contributed to increased profitability and capacity utilization [5][6].